Special Issue

Advancements in Induced Pluripotent Stem Cells

Message from the Guest Editor

Since the creation of induced pluripotent stem cells (iPSCs), by the Nobel Prize laureate Dr. Shinya Yamanaka, many laboratories worldwide are working to generate and apply these cells to the investigation of the ethiopathogeny behind diseases and the search for new therapies against them. The aim of this Special Issue is to collect high-quality papers, fully dedicated to iPSCs and their applications, from top experts in this field. We particularly encourage researchers to submit comprehensive review papers and original articles that showcase the latest advancements in this area. By doing so, we aim to create a collection of high-quality papers that explore the potential of iPSCs and shed light on their diverse applications in addressing various challenges in medical research and treatment.

- induced pluripotent stem cells
- organoids
- tissue engineering
- biomaterials
- reprogramming
- iPSC-based cell modelling
- cell therapy
- microfluidics
- drug discovery

Guest Editor

Dr. M. Esther Gallardo

Head of Translational Research with iPS Cells Group, Research Institute Hospital 12 de Octubre, i+12, Madrid, Spain

Deadline for manuscript submissions

closed (31 August 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/196408

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).